ClearPath DS-120

Uncontrolled Diabetes
Early Detection is Here

The CLEARPATH DS-120TM Detects Diabetes up to 7 Years Prior to Complications

Clear Lake Optometry is certified to use the the CLEARPATH DS-120TM, cleared by the U.S. Food and Drug Administration (FDA) in January 2013, the ClearPath DS-120 is a first-in-class, non-invasive tool designed to quickly and accurately measure crystalline lens autofluorescence through a six second scan of the eye. Autofluorescence of the lens of the eye can be used to detect diabetes up to seven years prior to the appearance of symptoms such as diabetic retinopathy.

The Evaluation is Fast and Non-Invasiveclearpath2

This non-invasive test represents a potential superior alternative to existing ophthalmic assessment tools by avoiding:

  • The need for dilation
  • A painful blood draw
  • The need for fasting prior to testing
  • The inconvenience of waiting several days for the test result

The Results are Immediate

After a successful scan, the patient’s fluorescence ratio measurement is displayed.

By identifying patients with elevated fluorescence ratios above the normal range, the clinician can identify potential risk of chronic systemic diseases such as diabetes.

High Value, Low Cost

Insurance benefits typically do not cover this advanced testing. The ClearPath test might be reimbursable through your flex benefits or Health Savings Account frequently offered by employers. Call us today for more information. 641-357-2020.